Companies: 10,795·Total market cap: $144.5T
Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals, Inc.

CYCCNASDAQHealthcare
$6.37
$-0.41(-5.98%)
Market Cap$10608329
P/E Ratio
52W High$597.59973
52W Low$3.0801
Overview

Cyclacel Pharmaceuticals, Inc. (CYCC) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001130166 · CYCC · NASDAQ · as of Jun 9, 2026

Filing snapshot

1,000+
Total Filings
425
Latest Form
2026-06-04
Most Recent
2004
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001130166 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-30
Fiscal Year End
Mar 30, 2026
Accession No.
0001493152-26-013669
Primary Document
form10-k.htm
Source: data.sec.gov · CIK 0001130166 · Accession 0001493152-26-013669

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-15
8-KCurrent Report
8-K
2026-06-04Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
425425
425
2026-06-04
View
8-KCurrent Report
8-K
2026-06-04
View
10-QQuarterly Report
10-Q
2026-05-15
View
8-KCurrent Report
8-K
2026-05-14
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-12
View
DEFR14ADEFR14A
DEFR14A
2026-05-01
View
DEF 14AProxy Statement
DEF 14A
2026-04-27
View
8-KCurrent Report
8-K
2026-04-13
View
10-KAnnual Report
10-K
2026-03-30
View
8-KCurrent Report
8-K
2026-03-30
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-13
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-13
View
8-KCurrent Report
8-K
2026-03-13
View
8-KCurrent Report
8-K
2026-01-12
View
S-8Employee Stock Plan Registration
S-8
2025-11-28
View
Showing 1–15 of 805 filingsForm 4 / 144 hidden· 1000 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001130166  |  Exchange: NASDAQ · Healthcare

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) has submitted 1,000+ documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2004. As a Healthcare sector company with CIK 0001130166, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Cyclacel Pharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent Cyclacel Pharmaceuticals, Inc. 10-K was filed on 2026-03-30 for fiscal year ending 2026. Historical CYCC 10-K annual reports are available from 2009 through 2026.

Investors researching Cyclacel Pharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

CYCC SEC Filings · 8 questions

Cyclacel Pharmaceuticals, Inc. (CYCC) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 1,000+ filings and access original documents at no cost. Cyclacel Pharmaceuticals, Inc.'s CIK is 0001130166.

CYCC SEC filingsCyclacel Pharmaceuticals, Inc. SEC documentsfind CYCC 10-K